Group 1 - The stock price of Sihuan Pharmaceutical has increased by over 3%, reaching HKD 32.16 with a trading volume of HKD 584 million [1] - Sihuan Pharmaceutical reported a revenue of RMB 4.4 billion for the first half of the year, a year-on-year decrease of 0.8%, primarily due to a slowdown in TPIAO sales, although this was partially offset by strong growth in its hair loss treatment product line [1] - The net profit attributable to shareholders increased by 24.6% to RMB 1.1 billion, benefiting from a 49% reduction in financial costs [1] Group 2 - The company expects to launch several new drugs between 2025 and 2026, including 608 (IL-17A inhibitor) and 613 (IL-1β inhibitor), which are anticipated to drive revenue growth [1] - The 707 (PD-1/VEGF dual antibody) is considered to have the potential to become a blockbuster drug globally, with Pfizer expected to actively promote its global clinical development and combination therapy [1] - The initiation of global clinical trials for 707 is expected to be a significant catalyst for the company's profit growth [1][2]
港股异动 | 三生制药(01530)再涨超3% 机构称707项目全球临床试验启动有望成为公司盈利上行重要催化剂